Dementia/Alzheimer Disease
RSSArticles
-
Cholecystokinin as a Biomarker Linking Metabolic Function to Alzheimer’s Disease
In a study cohort from the Alzheimer’s Disease Neuroimaging Initiative, cerebrospinal fluid levels of cholecystokinin were associated with better outcomes that may reflect compensatory protection as Alzheimer’s disease pathology progresses. However, because of significant study limitations, these findings need to be validated in additional studies.
-
Thinking Outside of the ‘Alpha-Synuclein Box’: A Critical Role of Tau in Lewy Body Disorders
Neocortical tau pathology was associated with worse antemortem cognition in this large study of Parkinson’s disease dementia and dementia with Lewy bodies. Regional brain variations correlated with specific cognitive domains.
-
Predicting the Risk of Mild Cognitive Impairment Using Imaging Biomarkers
In this population-based study, researchers used imaging biomarkers of amyloid and neuronal injury to estimate an absolute risk of mild cognitive impairment in the elderly.
-
Amyloid-ß Pathology Induced by Contaminated Cadaver-Derived Growth Hormone
Cadaveric pituitary-derived growth hormone that previously was known to transmit Creutzfeldt-Jakob disease (CJD) also contains ß-amyloid. Growth hormone vials from cases associated with amyloid plaques in CJD patients cause amyloid plaque formation and cerebral amyloid angiopathy when injected intracranially into mice.
-
Apolipoprotein E and CSF Levels in Men and Women With Alzheimer’s Disease
Apolipoprotein E epsilon 4 (APOE4) genotype, the stronger genetic risk factor for late-onset Alzheimer’s disease, negatively affects cerebrospinal levels of tau protein in a sex-dependent manner, whereby the effect of APOE4 is stronger in women than men.
-
Effect of Diet on Hippocampal Volume in a Population at Risk for Alzheimer’s Disease
Magnetic resonance imaging of the brain in community-dwelling people (average age of 60 years) found that a long-term, high-quality diet was associated with larger hippocampal volumes after an average interval of 11 years.
-
Predicting Future Dementia With Retinal Optical Coherence Tomography
Optical coherence tomography (OCT) is an innovative imaging device that measures thickness of retinal nerve fiber layers and ganglion cells. Thinning of these layers is associated with current and future risk of dementia.
-
Use of Amyloid PET Imaging for Diagnosis of Dementia
The use of amyloid positron emission tomography scanning to assist in accurate diagnosis of patients with symptoms of cognitive impairment as well as frank dementia results in a change of diagnosis in at least 25% of patients.
-
Predicting the Risk of Late-onset Alzheimer’s Disease and Dementia Based on Common Genetic Variants
Using a genetic risk score of 23 common genetic variants and apolipoprotein E genotype could help stratify individuals into those very likely to those very unlikely to develop late-onset Alzheimer’s disease and dementia.
-
Longitudinal tau PET as an Outcome Measure for Clinical Trials
tau PET imaging shows progression of brain Alzheimer’s pathology over time and correlates with cognitive impairment better than amyloid PET. In future clinical trials, tau PET can serve as a biomarker for Alzheimer’s disease progression.